Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-11-06FDA Approved: DASATINIB — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of dasatinib (DASATINIB) from Alembic Pharmaceuticals Limited under an Original Application. The approval mak…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL [Phase 1]
HQP1351 is being investigated in a Phase 1 trial for patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive …
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML [Phase 1]
This is a Phase 1 clinical trial assessing a quadruple combination of ABL001 (asciminib), dasatinib, prednisone, and blinatumomab in patient…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease [Phase 2]
Phase 2 trial assessing blinatumomab in adults with B-cell acute lymphoblastic leukemia in complete remission who have minimal residual dise…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Newly-diagnosed Pediatric Ph-positive B-ALL Protocol [Phase 3]
Phase 3 clinical trial protocol for newly diagnosed Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia, currently recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-08-27FDA Approved: DASATINIB — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva Pharmaceuticals' original application to market a generic dasatinib product.
-
FDA approval · 2025-08-25FDA Approved: DASATINIB — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin Pharmaceuticals' generic dasatinib (original ANDA) for the treatment of Philadelphia chromosome-positive chronic myeloid …
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. [EARLY_Phase 1]
An early Phase 1 trial assessing the safety, efficacy signals, and pharmacokinetics of ThisCART19A combined with olverembatinib in patients …
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older [Phase 1]
This clinical trial update describes adding ruxolitinib to a dasatinib plus dexamethasone induction regimen for newly diagnosed Philadelphia…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 clinical trial update evaluating asciminib as maintenance therapy after cellular therapies in adults with Philadelphia chromosome-po…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL [Phase 2]
A Phase 2 study evaluating olverembatinib with reduced-intensity chemotherapy and venetoclax for newly diagnosed Philadelphia chromosome–pos…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab plus blinatumomab for recurrent or refractory CD19-positive, Philadelphia chromosome-pos…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT [Phase 2]
Phase 2 randomized trial in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia evaluating chemotherap…
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved an original application for dasatinib from Zydus Pharmaceuticals USA Inc., enabling a generic version of the cancer drug. D…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. [Phase 2]
Phase 2 trial evaluating the combination of chemotherapy with dasatinib in Philadelphia chromosome–positive or BCR-ABL–positive acute lympho…
-
CLINICAL_TRIALS research · 2025-01-23Clinical Trial Update: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL [Phase 3]
A Phase 3 trial is comparing sequential ponatinib and blinatumomab against chemotherapy and imatinib in newly diagnosed adult Philadelphia c…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating ponatinib with chemotherapy in children, teenagers, and adults with Philadelphia chromosome–positive ALL,…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. [Phase 3]
A Phase 3 clinical trial is evaluating olverembatinib in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, with…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL [Phase 2]
This is a Phase 2 clinical trial evaluating olverembatinib as maintenance or preemptive therapy after allogeneic hematopoietic stem cell tra…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse [Phase 2]
Phase 2 study evaluating ponatinib in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, including MRD-positive and …
-
CLINICAL_TRIALS research · 2024-08-29Clinical Trial Update: Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL [Phase 2]
A Phase 2 clinical trial evaluating a chemotherapy-free combination of venetoclax, azacitidine, and orebatinib for newly diagnosed Philadelp…
-
CLINICAL_TRIALS withdrawal · 2024-08-14Clinical Trial Update: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL [Phase 2]
A Phase 2 trial evaluating ponatinib plus reduced-intensity chemotherapy as first-line therapy for adults with Philadelphia chromosome-posit…
-
FDA approval · 2024-07-31FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, resulting in an approved change to its labeling and/…
-
FDA approval · 2024-03-19FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) submitted by Takeda Pharmaceuticals America, Inc. The appr…
-
FDA approval · 2024-02-06FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TASIGNA (nilotinib) submitted by Novartis, resulting in changes to the labeling under the supple…